Idioma:

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

Landray, Martin J ; Haynes, Richard ; Hopewell, Jemma C ; Parish, Sarah ; Aung, Theingi ; Tomson, Joseph ; Wallendszus, Karl ; Craig, Martin ; Jiang, Lixin ; Collins, Rory ; Armitage, Jane

The New England journal of medicine, 2014-07, Vol.371 (3), p.203-212 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Autor: Landray, Martin J ; Haynes, Richard ; Hopewell, Jemma C ; Parish, Sarah ; Aung, Theingi ; Tomson, Joseph ; Wallendszus, Karl ; Craig, Martin ; Jiang, Lixin ; Collins, Rory ; Armitage, Jane
Assuntos: Aged ; Arteriosclerosis ; Atherosclerosis - drug therapy ; Biological and medical sciences ; Blood circulation disorders ; Cardiovascular disease ; Care and treatment ; Cerebral infarction ; Cholesterol ; Cholesterol, LDL - blood ; Delayed-Action Preparations ; Diabetes mellitus ; Diabetes Mellitus - chemically induced ; Dosage and administration ; Dose-response relationship (Biochemistry) ; Double-Blind Method ; Drug Combinations ; Drug dosages ; Female ; Follow-Up Studies ; General aspects ; Heart attacks ; Hemorrhage - chemically induced ; High density lipoprotein ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - drug therapy ; Hypolipidemic Agents - administration & dosage ; Hypolipidemic Agents - adverse effects ; Indoles - administration & dosage ; Indoles - adverse effects ; Infections - chemically induced ; Laropiprant ; Low density lipoprotein ; Male ; Medical sciences ; Medicin och hälsovetenskap ; Middle Aged ; Musculoskeletal Diseases - chemically induced ; Musculoskeletal system ; Myocardial infarction ; Niacin ; Niacin - administration & dosage ; Niacin - adverse effects ; Risk Factors ; Risk groups ; Skin ; Statins ; Stroke ; Treatment Failure ; Vascular diseases ; Vitamin B
É parte de: The New England journal of medicine, 2014-07, Vol.371 (3), p.203-212
Descrição: Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant or placebo. Niacin–laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events. Patients with cardiovascular disease remain at substantial risk for major vascular events despite current approaches to treatment of risk factors. 1 Observational data indicate that the low-density lipoprotein (LDL) cholesterol level is strongly positively associated with the risk of coronary heart disease and that the high-density lipoprotein (HDL) cholesterol level is strongly inversely associated. 2 High-dose niacin decreases the LDL cholesterol level and increases the HDL cholesterol level, as well as lowering triglyceride and lipoprotein(a) levels and blood pressure. 3 , 4 Current guidelines recommend that niacin therapy be considered for reducing cardiovascular risk, 5 , 6 and its use in the United States has been . . .
Editor: Waltham, MA: Massachusetts Medical Society
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

Landray, Martin J ; Haynes, Richard ; Hopewell, Jemma C ; Parish, Sarah ; Aung, Theingi ; Tomson, Joseph ; Wallendszus, Karl ; Craig, Martin ; Jiang, Lixin ; Collins, Rory ; Armitage, Jane

Waltham, MA: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.